SI3774897T1 - Postopki in sistemi za selekcijo in zdravljenje bolnikov z vnetnimi boleznimi - Google Patents

Postopki in sistemi za selekcijo in zdravljenje bolnikov z vnetnimi boleznimi

Info

Publication number
SI3774897T1
SI3774897T1 SI201930656T SI201930656T SI3774897T1 SI 3774897 T1 SI3774897 T1 SI 3774897T1 SI 201930656 T SI201930656 T SI 201930656T SI 201930656 T SI201930656 T SI 201930656T SI 3774897 T1 SI3774897 T1 SI 3774897T1
Authority
SI
Slovenia
Prior art keywords
patients
selection
systems
treatment
methods
Prior art date
Application number
SI201930656T
Other languages
English (en)
Inventor
Janine Bilsborough
Dermot P. Mcgovern
Stephan Targan
Alka Potdar
Jeffry D. Watkins
Cindy T. Dickerson
Original Assignee
Cedars-Sinai Medical Center
Prometheus Biosciences, Inc.,
Dr. Falk Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars-Sinai Medical Center, Prometheus Biosciences, Inc.,, Dr. Falk Pharma Gmbh filed Critical Cedars-Sinai Medical Center
Publication of SI3774897T1 publication Critical patent/SI3774897T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
SI201930656T 2018-04-30 2019-04-26 Postopki in sistemi za selekcijo in zdravljenje bolnikov z vnetnimi boleznimi SI3774897T1 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862664720P 2018-04-30 2018-04-30
US201862681557P 2018-06-06 2018-06-06
US201862784179P 2018-12-21 2018-12-21
PCT/US2019/029402 WO2019212899A1 (en) 2018-04-30 2019-04-26 Methods and systems for selection and treatment of patients with inflammatory diseases
EP19796203.8A EP3774897B1 (en) 2018-04-30 2019-04-26 Methods and systems for selection and treatment of patients with inflammatory diseases

Publications (1)

Publication Number Publication Date
SI3774897T1 true SI3774897T1 (sl) 2024-01-31

Family

ID=68386125

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201930656T SI3774897T1 (sl) 2018-04-30 2019-04-26 Postopki in sistemi za selekcijo in zdravljenje bolnikov z vnetnimi boleznimi

Country Status (21)

Country Link
US (1) US20210238684A1 (sl)
EP (2) EP3774897B1 (sl)
JP (1) JP2021532060A (sl)
KR (1) KR20210013062A (sl)
CN (1) CN112368301A (sl)
AU (1) AU2019261933A1 (sl)
CA (1) CA3098720A1 (sl)
DK (1) DK3774897T3 (sl)
ES (1) ES2962715T3 (sl)
FI (1) FI3774897T3 (sl)
HR (1) HRP20231367T1 (sl)
HU (1) HUE063908T2 (sl)
LT (1) LT3774897T (sl)
MA (1) MA52251A (sl)
MD (1) MD3774897T2 (sl)
PL (1) PL3774897T3 (sl)
PT (1) PT3774897T (sl)
RS (1) RS64747B1 (sl)
SI (1) SI3774897T1 (sl)
TW (1) TW202003573A (sl)
WO (1) WO2019212899A1 (sl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024509746A (ja) * 2021-02-17 2024-03-05 プロメテウス バイオサイエンシーズ，インク． 抗ｃｄ３０ｌ抗体およびその使用
WO2024026395A1 (en) * 2022-07-27 2024-02-01 Cephalon Llc Anti-tl1a antibodies for the treatment of ulcerative colitis and crohn's disease
WO2024026386A1 (en) * 2022-07-27 2024-02-01 Cephalon Llc Anti-tl1a antibody formulations

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
US4476116A (en) 1982-12-10 1984-10-09 Syntex (U.S.A.) Inc. Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
US5116817A (en) 1982-12-10 1992-05-26 Syntex (U.S.A.) Inc. LHRH preparations for intranasal administration
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
EP0230654B1 (en) 1985-12-28 1992-03-18 Sumitomo Pharmaceuticals Company, Limited Sustained pulsewise release pharmaceutical preparation
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5739136A (en) 1989-10-17 1998-04-14 Ellinwood, Jr.; Everett H. Intraoral dosing method of administering medicaments
US5017381A (en) 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
US5229135A (en) 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
US6652854B2 (en) * 2000-08-08 2003-11-25 Immunex Corporation Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L
US6960563B2 (en) 2001-08-31 2005-11-01 Morton Grove Pharmaceuticals, Inc. Spontaneous emulsions containing cyclosporine
US20060194265A1 (en) * 2001-10-23 2006-08-31 Morris David W Novel therapeutic targets in cancer
WO2008106451A2 (en) * 2007-02-26 2008-09-04 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
US20120225427A1 (en) * 2009-08-21 2012-09-06 Inserm (Institut National De La Sante Et De La Recherche Medicale) sPLA2 IIA Polymorphism Analysis for the Diagnosis/Prognosis of a Cardiovascular Disease/Event
DK2841456T3 (en) * 2012-04-27 2018-08-13 Novo Nordisk As HUMAN CD30 LIGAND ANTI-BINDING PROTEINS
WO2013181694A1 (en) * 2012-06-04 2013-12-12 Gaurav Agrawal Compositions and methods for treating crohn's disease and related conditions and infections
MY191324A (en) * 2016-10-26 2022-06-15 Cedars Sinai Medical Center Neutralizing anti-tl1a monoclonal antibodies

Also Published As

Publication number Publication date
ES2962715T3 (es) 2024-03-20
EP3774897B1 (en) 2023-09-27
PL3774897T3 (pl) 2024-01-29
MA52251A (fr) 2021-02-17
CA3098720A1 (en) 2019-11-07
DK3774897T3 (da) 2023-11-06
PT3774897T (pt) 2023-11-10
FI3774897T3 (fi) 2023-11-03
HUE063908T2 (hu) 2024-02-28
HRP20231367T1 (hr) 2024-02-16
MD3774897T2 (ro) 2024-02-29
CN112368301A (zh) 2021-02-12
AU2019261933A1 (en) 2020-12-03
EP4296285A2 (en) 2023-12-27
EP4296285A3 (en) 2024-02-28
KR20210013062A (ko) 2021-02-03
EP3774897A4 (en) 2022-02-16
JP2021532060A (ja) 2021-11-25
EP3774897A1 (en) 2021-02-17
TW202003573A (zh) 2020-01-16
US20210238684A1 (en) 2021-08-05
LT3774897T (lt) 2023-11-10
WO2019212899A1 (en) 2019-11-07
RS64747B1 (sr) 2023-11-30

Similar Documents

Publication Publication Date Title
ZA201906485B (en) Treatment of inflammatory diseases with inhibitors of c5a activity
EP3506926A4 (en) NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC PROCEDURES FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES
IL262608A (en) Combined treatment of eye disorders and inflammatory diseases
HK1258914A1 (zh) 2-取代的吲唑用於治療和預防自身免疫疾病的用途
EP3749344A4 (en) METHODS OF THERAPEUTIC USE OF EXOSOMES AND YRNA
IL276383A (en) Treatment of ophthalmological diseases
EP3503903A4 (en) ASCAROSIDE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES
ZA201906213B (en) Compounds and methods for the treatment of parasitic diseases
IL271074A (en) Treatment of inflammatory diseases with c5a activity inhibitors
ZA202101587B (en) Protein for treatment of inflammatory diseases
SG11202103567RA (en) Methods of treatment of inflammatory conditions and associated infections
LT3774897T (lt) Pacientų, sergančių uždegiminėmis ligomis, atrankos ir gydymo būdai bei sistemos
EP3866777A4 (en) COMBINATION THERAPIES FOR THE TREATMENT OF INFLAMMATORY DISEASES
EP3472181A4 (en) METHOD FOR DIAGNOSIS AND TREATMENT OF AUTOIMMUNE DISEASES
HK1255691A1 (zh) 對疾病進行組織學診斷和治療的方法
GB202015959D0 (en) Treatment of diseases involving NAD
RS64455B1 (sr) Peptidi koji vezuju bakterije, za lečenje infektivnih bolesti i povezanih inflamatornih procesa
GB201805100D0 (en) Treatment of sarcopenic diseases
EP3411479A4 (en) TREATMENT AND DIAGNOSIS OF INFLAMMATORY DISORDERS
EP3863621A4 (en) COMBINATION THERAPY FOR THE TREATMENT AND PREVENTION OF AUTOIMMUNE AND INFLAMMATION DISEASES
GB2603379B (en) Avocatin B for the treatment of diseases and conditions
EP3356561A4 (en) THERAPEUTIC AND DIAGNOSTIC METHODS FOR AUTOIMMUNE DISEASES AND / OR INFLAMMATIONS
AU2018903815A0 (en) Combination therapy for treatment and prevention of autoimmune and inflammatory diseases
EP4003283C0 (en) TREATMENT OF INFLAMMATORY SKIN CONDITIONS
EP3781688A4 (en) APTAMERATES TARGETING TNF FACTOR AND THEIR USES FOR THE TREATMENT OR DIAGNOSIS OF INFLAMMATORY DISEASES ASSOCIATED WITH TNF